重组人血管内皮抑素联合多西紫杉醇治疗胃癌恶性腹腔积液的疗效  

Clinical observation of Endostar combined with docetaxel in the treatment of malignant ascites of gastric cancer

作　　者：陈磊[1] 丁德权[1] 何昌霞[1] 

机构地区：[1]安徽省马鞍山市人民医院肿瘤介入科,马鞍山243000

出　　处：《中国肿瘤临床与康复》2015年第10期1215-1217,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨重组人血管内皮抑素（恩度）联合多西紫杉醇治疗胃癌恶性腹腔积液的近期疗效和不良反应。方法选取2011年5月至2013年5月间收治的27例胃癌患者,采用重组人血管内皮抑素联合多西紫杉醇腹腔灌注化疗,引流腹腔积液后,腹腔注射注入重组人血管内皮抑素60 mg和多西紫杉醇40 mg/m2,第1、8天,3~4周重复,2个周期后评价1次疗效及不良反应。结果27例患者治疗后完全缓解2例、部分缓解15例、稳定4例、进展6例,疾病控制率（DCR）为77.8%（21/27）,中位无疾病进展时间（m TTP）为4.2个月,中位生存期（OS）为7.6个月。主要不良反应为骨髓抑制、消化道反应及乏力。结论重组人血管内皮抑素联合多西紫杉醇治疗胃癌恶性腹腔积液疗效确切,不良反应发生率低,耐受性好。Objective To explore the curative effect and adverse reaction of Endostar combined with docetaxel in the treatment of malignant ascites of gastric cancer. Methods From May 2011 to May2013 in People＇s Hospital of Ma＇anshan,27 advanced gastric cancer patients with malignant ascites were enrolled in the study. They all used Endostar combined with docetaxel intraperitoneal perfusion chemotherapy.After drainage of peritoneal effusion,Endostar 60 mg and docetaxel 40 mg / m2 were injected,d1,8,3 ~ 4wk. The efficacy was evaluated every 2 wk. Results Among the 27 cases,2 cases achieved complete remission,15 cases partial remission,4 cases stable disease,6 cases progressive disease. The disease control rate was 77. 8%（ 21 /27）; the median progression free survival time was 4. 2 mo,and the median survival time was 7. 6 mo. The main adverse reactions were bone marrow suppression,gastrointestinal reactions and fatigue. Conclusion Endostar combined with docetaxel in the treatment of malignant ascites of gastric cancer could achieve better curative effect and low incidence of adverse reactions.

关 键 词：重组人血管内皮抑素 多西紫杉醇 腹膜转移 胃肿瘤 

分 类 号：R735.2[医药卫生—肿瘤]